Skip to main content
. Author manuscript; available in PMC: 2009 Sep 15.
Published in final edited form as: Stroke. 2008 Nov 20;40(2):604–609. doi: 10.1161/STROKEAHA.108.522409

Figure 3.

Figure 3

The doses of glibenclamide used are not hypoglycemogenic. A–B, Serum glucose levels at various times for vehicle-treated rats and rats treated with glibenclamide 5¾ hours post-MCAo (temporary MCAo series; loading dose, 10 μg/mL; infusion dose, 200 ng/h; A) and for sham rats (no MCAo) administered a higher dose (loading dose, 80 μg/mL; infusion dose, 600 ng/h; B).